details

The knowledge on breast cancer diseases is growing rapidly. In order to keep up to date with the plethora of information, the National Center for Tumor Diseases (NCT) Heidelberg invites physicians and scientists to the symposium “The Mamma carcinoma – State of the art diagnostics, therapy and follow-up care” on February 11. The Medical Chamber recognizes the event as further education. Advance registration is requested.

The NCT Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), the Heidelberg University Hospital (UKHD) and the German Cancer Aid.

Worldwide, scientists and physicians work on bringing new diagnostic procedures and therapies to patients. This road isn’t always easy because of the complex matter and also due to the lack of the expert’s networking. “We want to bring physicians and researchers together and support the scientific exchange”, explains Dirk Jäger, managing and medical director at the National Center for Tumor Diseases (NCT) Heidelberg, the goal of the spring symposium.

Breast cancer has become a disease that can be well treated. “Breast cancer-specific survival at five years is currently 90% in certified breast centers. 20 – 30% of all patients die of this disease in Germany today and cure rate is bought with a massive over-therapy”, says professor Andreas Schneeweiss about the current situation in Germany. The goal is to develop a therapy that is tailored to each patient individually. Schneeweiss is Head of Gynecological Oncology at the NCT Heidelberg and University Women’s Hospital (executive director: Christof Sohn). Together with Dirk Jäger he took over the scientific management of the symposium.

The event will start at 9 am on February 11, the end is planned for 1:30 pm. Afterwards, the NCT invites to a culinary finish. In 11 presentations, 15 speakers from the NCT will present updates in prevention, diagnostics and therapy of the mamma carcinoma. Participations will be rewarded by the Medical Chamber with further education credits. The spring symposium will take place at the communication center of the German Cancer Research Center (DKFZ) in Heidelberg. The event is not public and is meant for a professional audience. Participants can register online until the 10th of February: www.nct-heidelberg.de/anmeldung or per Mail an hso@nct-heidelberg.de 

Contact
Further Education and Event organization
Nationales Centrum für Tumorerkrankungen (NCT)
Heidelberg School of Oncology
Im Neuenheimer Feld 460
69120 Heidelberg
Tel.: +49 6221 56-6558
Fax: +49 6221 56-5094
hso@nct-heidelberg.de 

Location
Deutsches Krebsforschungszentrum (DKFZ)
Kommunikationszentrum, Großer Hörsaal
Im Neuenheimer Feld 280
69120 Heidelberg

The program can be found online:
https://www.nct-heidelberg.de/fileadmin/media/news/Meldungen/Dateien/NCT_FJS_2017_Flyer.pdf
Journalists are invited. Please inform of your arrival and possibly your interview requests us in advance. Your contact is Dr. Friederike Fellenberg, NCT PR, Tel. +49 (0)6221 56-5930, friederike.fellenberg@nct-heidelberg.de.

Press contacts:
Dr. Friederike Fellenberg
Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg
Presse- und Öffentlichkeitsarbeit
Im Neuenheimer Feld 460
69120 Heidelberg
Tel.: +49 6221 56-5930
Fax: +49 6221 56-5350
E-Mail: friederike.fellenberg@nct-heidelberg.de
www.nct-heidelberg.de

Dr. Stefanie Seltmann
Deutsches Krebsforschungszentrum (DKFZ)
Presse- und Öffentlichkeitsarbeit
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 280
69120 Heidelberg
Tel.: +49 6221 42-2854
Fax: +49 6221 42-2968
E-Mail: S.Seltmann@dkfz.de
www.dkfz.de

Doris Rübsam-Brodkorb
Universitätsklinikum Heidelberg und Medizinische Fakultät der Universität Heidelberg
Presse- und Öffentlichkeitsarbeit
Im Neuenheimer Feld 672
69120 Heidelberg
Tel.: +49 6221 56-5052
Fax: +49 6221 56-4544
E-Mail: doris.ruebsam-brodkorb@med.uni-heidelberg.de
www.klinikum.uni-heidelberg.de 

The National Center for Tumor Diseases (NCT) Heidelberg
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center, Heidelberg University Hospital and German Cancer Aid. The NCT's goal is to link promising approaches from cancer research with patient care from diagnosis to treatment, aftercare and prevention. The interdisciplinary tumor outpatient clinic is the central element of the NCT. Here the patients benefit from an individual treatment plan prepared in a timely manner in interdisciplinary expert rounds, the so-called tumor boards. Participation in clinical studies provides access to innovative therapies. The NCT thereby acts as a pioneering platform that translates novel research results from the laboratory into clinical practice. The NCT cooperates with self-help groups and supports them in their work. 2015 the NCT Heidelberg established a partner location in Dresden.

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)
The German Cancer Research Center (DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.

Heidelberg University Hospital and Medical Faculty Heidelberg
Heidelberg University Hospital is one of the most important medical centers in Germany; Heidelberg University's Medical Faculty is one of Europe's most prestigious biomedical research facilities. Their shared objective is the development of innovative diagnostics and treatments and their prompt implementation for the benefit of the patient. The hospital and faculty employ approximately 12 600 individuals and are involved in training and qualification. Every year approximately 66 000 patients are treated as inpatients or day patients in more than 50 specialized clinical departments with about 1 900 beds, with more than 1 million patients being treated as outpatients. The Heidelberg Curriculum Medicinale (HeiCuMed) is at the forefront of medical training in Germany. At present approx. 3500 prospective physicians are studying in Heidelberg.